{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:49:30Z","timestamp":1793191770632,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ejps.2025.107162","type":"journal-article","created":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T18:27:16Z","timestamp":1749320836000},"page":"107162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Model-informed drug development of Mim8 \u2013 a next-generation bispecific antibody for treatment of haemophilia A"],"prefix":"10.1016","volume":"212","author":[{"given":"Mads","family":"Kreilgaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Matytsina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Persson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2025.107162_bib0001","doi-asserted-by":"crossref","first-page":"570","DOI":"10.25122\/jml-2022-0103","article-title":"Expert opinion on current and future prophylaxis therapies aimed at improving protection for people with hemophilia A","volume":"15","author":"Batorova","year":"2022","journal-title":"J. Med. Life"},{"key":"10.1016\/j.ejps.2025.107162_bib0002","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-021-00278-x","article-title":"Haemophilia","volume":"7","author":"Berntorp","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ejps.2025.107162_bib0003","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1055\/a-1499-0030","article-title":"Emicizumab dosing in children and adults with hemophilia A: simulating a user-friendly and cost-efficient regimen","volume":"122","author":"Bukkems","year":"2022","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ejps.2025.107162_bib0004","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1055\/a-1424-7900","article-title":"Nonfactor therapies: new approaches to prophylactic treatment of haemophilia","volume":"41","author":"Chowdary","year":"2021","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.ejps.2025.107162_bib0006","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/cpt.3150","article-title":"Subcutaneous administration of monoclonal antibodies: pharmacology, delivery, immunogenicity, and learnings from applications to clinical development","volume":"115","author":"Davis","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2025.107162_bib0007","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2285277","article-title":"Monoclonal antibody and protein therapeutic formulations for subcutaneous delivery: high-concentration, low-volume vs. low-concentration, high-volume","volume":"15","author":"Desai","year":"2023","journal-title":"MAbs"},{"key":"10.1016\/j.ejps.2025.107162_bib0008","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s40262-021-01042-w","article-title":"Pharmacokinetics and associated efficacy of Emicizumab in humans: a systematic review","volume":"60","author":"Donners","year":"2021","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2025.107162_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100074","article-title":"The efficacy of the entire-vial dosing of emicizumab: real-world evidence on plasma concentrations, bleeds, and drug waste","volume":"7","author":"Donners","year":"2023","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"10.1016\/j.ejps.2025.107162_bib0010","unstructured":"European Medicines Agency, 2024. Hemlibra (emicizumab) summary of product characteristics. Retrieved from https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/hemlibra. Accessed June 11, 2025."},{"key":"10.1016\/j.ejps.2025.107162_bib0011","unstructured":"Food and Drug Administration, 2019. Actemra (tocilizumab) labeling-package insert. Retrieved from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125276s114lbl.pdf. Accessed June 11, 2025."},{"key":"10.1016\/j.ejps.2025.107162_bib0012","unstructured":"Food and Drug Administration, 2024. Hemlibra (emicizumab) labeling-package insert. Retrieved from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761083s000lbl.pdf. Accessed June 11, 2025."},{"issue":"Suppl 3","key":"10.1016\/j.ejps.2025.107162_bib0013","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/hae.14983","article-title":"Women and girls with inherited bleeding disorders: focus on haemophilia carriers and heavy menstrual bleeding","volume":"30","author":"Hermans","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.ejps.2025.107162_bib0014","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00003088-199630050-00001","article-title":"A size standard for pharmacokinetics","volume":"30","author":"Holford","year":"1996","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2025.107162_bib0015","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7326\/M19-1208","article-title":"Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries","volume":"171","author":"Iorio","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejps.2025.107162_bib0016","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.1182\/bloodadvances.2024013866","article-title":"Proactive systematic hemophilia carrier screening: a step towards gender equity in hemophilia care","volume":"8","author":"Krumb","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.ejps.2025.107162_bib0017","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1111\/jth.15682","article-title":"A novel next-generation FVIIIa mimetic, Mim8, has a favorable safety profile and displays potent pharmacodynamic effects: results from safety studies in cynomolgus monkeys","volume":"20","author":"Lauritzen","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ejps.2025.107162_bib0018","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jtha.2023.12.016","article-title":"FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimetic","volume":"22","author":"Lentz","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ejps.2025.107162_bib0019","doi-asserted-by":"crossref","first-page":"19","DOI":"10.12793\/tcp.2019.27.1.19","article-title":"Evolving role of modeling and simulation in drug development","volume":"27","author":"Lim","year":"2019","journal-title":"Transl. Clin. Pharmacol."},{"issue":"Suppl 4","key":"10.1016\/j.ejps.2025.107162_bib0020","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/hae.14524","article-title":"Emicizumab state-of-the-art update","volume":"28","author":"Mahlangu","year":"2022","journal-title":"Haemophilia"},{"issue":"Suppl 1","key":"10.1016\/j.ejps.2025.107162_bib0021","first-page":"S193","article-title":"Pediatric dose selection for therapeutic proteins","volume":"61","author":"Malik","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107162_bib0022","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1080\/13696998.2022.2115777","article-title":"Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe","volume":"25","author":"Mancuso","year":"2022","journal-title":"J. Med. Econ."},{"issue":"Suppl 3","key":"10.1016\/j.ejps.2025.107162_bib0023","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/hae.14976","article-title":"Benefits and risks of non-factor therapies: redefining haemophilia treatment goals in the era of new technologies","volume":"30","author":"Mancuso","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.ejps.2025.107162_bib0024","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/11530560-000000000-00000","article-title":"Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development","volume":"24","author":"Mould","year":"2010","journal-title":"BioDrugs"},{"key":"10.1016\/j.ejps.2025.107162_bib0025","series-title":"Medications in Single-Dose Vials: Implications of Discarded Drugs","first-page":"31","article-title":"Single-Dose Vials of Weight-Based Drugs","author":"Nass","year":"2021"},{"key":"10.1016\/j.ejps.2025.107162_bib0026","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12929-021-00760-4","article-title":"Advances in the management of haemophilia: emerging treatments and their mechanisms","volume":"28","author":"Okaygoun","year":"2021","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.ejps.2025.107162_bib0027","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood.2020010331","article-title":"A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice","volume":"138","author":"\u00d8stergaard","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2025.107162_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.102181","article-title":"Mim8, a novel factor VIIIa mimetic bispecific antibody, shows favorable safety and pharmacokinetics in healthy adults","volume":"7","author":"Persson","year":"2023","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"10.1016\/j.ejps.2025.107162_bib0029","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s40262-020-00904-z","article-title":"Population pharmacokinetic analysis and exploratory exposure-bleeding rate relationship of Emicizumab in adult and pediatric persons with hemophilia A","volume":"59","author":"Retout","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2025.107162_bib0030","doi-asserted-by":"crossref","first-page":"5630","DOI":"10.1182\/blood-2022-163554","article-title":"Mim8 Clinical Development Program: an overview of the frontier stud","volume":"140","author":"Seremetis","year":"2022","journal-title":"Blood"},{"issue":"Suppl 6","key":"10.1016\/j.ejps.2025.107162_bib0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.ejps.2025.107162_bib0032","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s40744-020-00245-0","article-title":"Understanding and minimising injection-site pain following subcutaneous administration of biologics: a narrative review","volume":"7","author":"St Clair-Jones","year":"2020","journal-title":"Rheumatol. Ther."},{"key":"10.1016\/j.ejps.2025.107162_bib0033","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40272-020-00382-7","article-title":"Pharmacokinetics and clinical pharmacology of monoclonal antibodies in pediatric patients","volume":"22","author":"Temrikar","year":"2020","journal-title":"Paediatr. Drugs"},{"key":"10.1016\/j.ejps.2025.107162_bib0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-023-01332-5","article-title":"Patients with obesity should be recognised as a special patient population during drug development of antibacterial and antifungal agents; A call to action","volume":"63","author":"van Rhee","year":"2024","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2025.107162_bib0035","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1177\/0091270009337512","article-title":"Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials","volume":"49","author":"Wang","year":"2009","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107162_bib0036","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.iccn.2017.02.003","article-title":"Evaluating the impact of obesity on safety and efficacy of weight-based norepinephrine dosing in septic shock: a single-center, retrospective study","volume":"41","author":"Wong","year":"2017","journal-title":"Intensive Crit. Care Nurs."},{"key":"10.1016\/j.ejps.2025.107162_bib0037","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s40262-017-0616-3","article-title":"A pharmacometric approach to substitute for a conventional dose-finding study in rare diseases: example of phase III dose selection for Emicizumab in Hemophilia A","volume":"57","author":"Yoneyama","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2025.107162_bib0038","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1038\/psp.2014.38","article-title":"Model-based assessment of dosing strategies in children for monoclonal antibodies exhibiting target-mediated drug disposition","volume":"3","author":"Zheng","year":"2014","journal-title":"CPT Pharmacometrics Syst. Pharmacol."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725001617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725001617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T10:13:56Z","timestamp":1757844836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098725001617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":37,"alternative-id":["S0928098725001617"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107162","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Model-informed drug development of Mim8 \u2013 a next-generation bispecific antibody for treatment of haemophilia A","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107162","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107162"}}